NO20073807L - Stabilisering av virussammensetninger - Google Patents
Stabilisering av virussammensetningerInfo
- Publication number
- NO20073807L NO20073807L NO20073807A NO20073807A NO20073807L NO 20073807 L NO20073807 L NO 20073807L NO 20073807 A NO20073807 A NO 20073807A NO 20073807 A NO20073807 A NO 20073807A NO 20073807 L NO20073807 L NO 20073807L
- Authority
- NO
- Norway
- Prior art keywords
- virus
- stabilization
- virus compositions
- compositions
- attenuated
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/021,289 US20060141483A1 (en) | 2004-12-23 | 2004-12-23 | Stabilization of viral compositions |
| PCT/US2005/041062 WO2006071373A1 (en) | 2004-12-23 | 2005-11-14 | Stabilization of viral compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073807L true NO20073807L (no) | 2007-08-15 |
Family
ID=36612101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073807A NO20073807L (no) | 2004-12-23 | 2007-07-20 | Stabilisering av virussammensetninger |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060141483A1 (ja) |
| EP (1) | EP1848398A4 (ja) |
| JP (1) | JP2008525444A (ja) |
| KR (1) | KR20070117542A (ja) |
| AU (1) | AU2005322522A1 (ja) |
| CA (1) | CA2592323A1 (ja) |
| MX (1) | MXPA05008695A (ja) |
| NO (1) | NO20073807L (ja) |
| WO (1) | WO2006071373A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007035455A2 (en) * | 2005-09-16 | 2007-03-29 | Merial Limited | Stabilizers for freeze-dried vaccines |
| TW201233803A (en) * | 2010-12-02 | 2012-08-16 | Oncolytics Biotech Inc | Lyophilized viral formulations |
| JP6034798B2 (ja) | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク，インコーポレーテッド | 液体ウイルス製剤 |
| CN108588035A (zh) * | 2011-06-28 | 2018-09-28 | 白血球保健股份有限公司 | 病毒或细菌的新型稳定方法 |
| LT2741740T (lt) | 2011-08-12 | 2017-08-10 | Merial, Inc. | Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas |
| EP3246400B1 (en) | 2012-01-09 | 2019-10-23 | Sanofi Pasteur Biologics, LLC | Purification of herpes virus |
| WO2013177172A2 (en) * | 2012-05-21 | 2013-11-28 | Sanofi Pasteur Limited | Herpesvirus compositions and related methods |
| KR102549746B1 (ko) * | 2014-12-18 | 2023-07-03 | 암젠 인크 | 안정한 동결된 단순 포진 바이러스 제제 |
| JPWO2021020446A1 (ja) * | 2019-07-30 | 2021-02-04 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147772A (en) * | 1976-02-03 | 1979-04-03 | Merck & Co., Inc. | Vaccine stabilizer |
| PT71926B (en) * | 1979-10-29 | 1982-03-31 | Merck & Co Inc | Process for preparing a liquid vaccine comprising a stabilizer |
| US4337242A (en) * | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| US4537769A (en) * | 1982-04-06 | 1985-08-27 | American Cyanamid Company | Stabilization of influenza virus vaccine |
| JPS63307827A (ja) * | 1987-06-08 | 1988-12-15 | Kitasato Inst:The | 安定化された生ウイルスワクチンおよびその製造法 |
| JPH0761955B2 (ja) * | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | 凍結乾燥ａ型肝炎ワクチン |
| DK0487632T3 (da) * | 1989-08-15 | 1998-05-25 | Massachusetts Inst Technology | Stabiliserede vaccinesammensætninger |
| AU2309692A (en) * | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| AU2088992A (en) * | 1992-05-05 | 1993-11-11 | Research Foundation For Microbial Diseases Of Osaka University, The | Stabilized live vaccine |
| JPH06234659A (ja) * | 1992-05-05 | 1994-08-23 | Handai Biseibutsubiyou Kenkyukai | 安定化生ワクチン |
| CA2158935A1 (en) * | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
| US6013265A (en) * | 1996-10-22 | 2000-01-11 | University Of Maryland, Baltimore | Vaccine composition for herpes simplex virus and methods of using |
| US6054131A (en) * | 1998-01-16 | 2000-04-25 | University Of Maryland Baltimore | Vaccine composition for herpes simplex virus and method of using |
| GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| US6231889B1 (en) * | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
-
2004
- 2004-12-23 US US11/021,289 patent/US20060141483A1/en not_active Abandoned
-
2005
- 2005-08-16 MX MXPA05008695A patent/MXPA05008695A/es not_active Application Discontinuation
- 2005-11-14 WO PCT/US2005/041062 patent/WO2006071373A1/en active Application Filing
- 2005-11-14 KR KR1020077016708A patent/KR20070117542A/ko not_active Application Discontinuation
- 2005-11-14 AU AU2005322522A patent/AU2005322522A1/en not_active Abandoned
- 2005-11-14 JP JP2007548224A patent/JP2008525444A/ja active Pending
- 2005-11-14 EP EP05851578A patent/EP1848398A4/en not_active Withdrawn
- 2005-11-14 CA CA 2592323 patent/CA2592323A1/en not_active Abandoned
-
2007
- 2007-07-20 NO NO20073807A patent/NO20073807L/no not_active Application Discontinuation
-
2008
- 2008-06-09 US US12/135,922 patent/US20080241187A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005322522A1 (en) | 2006-07-06 |
| US20080241187A1 (en) | 2008-10-02 |
| EP1848398A1 (en) | 2007-10-31 |
| KR20070117542A (ko) | 2007-12-12 |
| MXPA05008695A (es) | 2008-03-07 |
| EP1848398A4 (en) | 2010-02-24 |
| JP2008525444A (ja) | 2008-07-17 |
| CA2592323A1 (en) | 2006-07-06 |
| US20060141483A1 (en) | 2006-06-29 |
| WO2006071373A1 (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073807L (no) | Stabilisering av virussammensetninger | |
| HK1207828A1 (en) | Cell-derived viral vaccines with low levels of residual cell dna dna | |
| NO20070551L (no) | Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon. | |
| MY156422A (en) | Methods and compositions for live attenuated viruses | |
| NO20081889L (no) | Fast vaksine formulering | |
| WO2004041201A3 (en) | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases | |
| CY1115749T1 (el) | Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια | |
| WO2008133663A3 (en) | Codon modified immunogenic compositions and methods of use | |
| EP2336174B8 (en) | Human monoclonal antibodies against Hendra and Nipah viruses | |
| BR0306925A (pt) | Formulações estabilizadas de adenovìrus | |
| WO2007044024A3 (en) | Recombinant influenza vectors with tandem transcription units | |
| NO20044941L (no) | Modifisert vacciniavirus Ankara til vaksinasjon av nyfodte | |
| WO2006124700A3 (en) | P53 vaccines for the treatment of cancers | |
| WO2006110887A3 (en) | Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling | |
| WO2008156778A3 (en) | Influenza m2 protein mutant viruses as live influenza attenuated vaccines | |
| WO2007084435A3 (en) | Methods for treating hepatitis c | |
| BE1023213B1 (fr) | Complexes issus du cytomegalovirus et leurs utilisations | |
| WO2010068968A8 (en) | Methods and compositions for use of a coccidiosis vaccine | |
| EA201390812A1 (ru) | Лиофилизированные вирусные составы | |
| EA201000277A1 (ru) | Соединения для лечения гепатита с | |
| WO2009067191A3 (en) | Methods and compositions for the treatment of hepatitis c virus (hcv) infection | |
| WO2009080715A3 (en) | Vaccines for malaria | |
| WO2003023040A3 (en) | Vaccinia virus mva-e3l-knockout-mutants and use thereof | |
| WO2008048984A3 (en) | Methods and compositions for preparing a universal influenza vaccine | |
| WO2009120339A3 (en) | Vectors for delivering disease neutralizing agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |